<DOC>
	<DOCNO>NCT00564174</DOCNO>
	<brief_summary>To compare livebirth rate woman recurrent pregnancy loss autoantibody randomize either low molecular weight heparin plus aspirin versus aspirin alone .</brief_summary>
	<brief_title>Low Molecular Weight Heparin Aspirin Treatment Recurrent Pregnancy Loss : A RCT</brief_title>
	<detailed_description>Previous study therapeutic regimen population recurrent pregnancy loss autoantibody , provide conclusive evidence efficacy due small sample size and/or weak study design . We undertake RCT low molecular weight heparin plus aspirin versus aspirin alone investigate low molecular weight heparin treatment result increased rate livebirths compare treatment aspirin alone .</detailed_description>
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Antiphospholipid Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<criteria>history two unexplained consecutive pregnancy loss prior 32 week presence one panel autoantibodies/thrombophilia marker confirm pregnancy SLE know peptic ulcer disease sensitivity ASA heparin previous thrombotic event geographic distance clinic failure consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>recurrent pregnancy loss</keyword>
	<keyword>lupus anticoagulant</keyword>
	<keyword>anti cardiolipin antibody</keyword>
	<keyword>thrombophilia</keyword>
	<keyword>low molecular weight heparin</keyword>
	<keyword>aspirin</keyword>
	<keyword>randomize clinical trial</keyword>
</DOC>